These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31570241)

  • 21. von Willebrand disease: treatment with or without factor VIII?
    Konkle BA
    J Thromb Haemost; 2007 Jun; 5(6):1113-4. PubMed ID: 17590904
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.
    Lubetsky A; Martinowitz U; Luboshitz J; Kenet G; Keller N; Tamarin I; Inbal A
    Haemophilia; 2002 Sep; 8(5):622-8. PubMed ID: 12199669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G; Eberspächer B; Engl W; Güthner C; Koksch M; Kreuz W; Nimtz A; Pindur G; Scheel H; Schreiber JD; Siekmann J; Turecek PL; Wolf HH
    Semin Thromb Hemost; 2002 Apr; 28(2):203-14. PubMed ID: 11992243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
    Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
    Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards personalised therapy for von Willebrand disease: a future role for recombinant products.
    Favaloro EJ
    Blood Transfus; 2016 May; 14(2):262-76. PubMed ID: 27136426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of von Willebrand factor in platelets of patients with various forms of von Willebrand disease: is there a clinical relevance?
    Kertzscher F; Müller AE; Lenk H
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S177-9. PubMed ID: 10650864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A von Willebrand factor/factor VIII complex restores platelet adhesion and fibrin formation in type 3 von Willebrand syndrome.
    Arderiu G; Díaz-Ricart M; Aznar-Salatti J; Escolar G; Ordinas A
    J Thromb Haemost; 2003 Apr; 1(4):865-6. PubMed ID: 12871435
    [No Abstract]   [Full Text] [Related]  

  • 29. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.
    Caron C; Mazurier C; Goudemand J
    Br J Haematol; 2002 Jun; 117(3):716-8. PubMed ID: 12028048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease--results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
    Mazurier C; Meyer D
    Thromb Haemost; 1996 Aug; 76(2):270-4. PubMed ID: 8865544
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.
    Cushing M; Kawaguchi K; Friedman KD; Mark T
    Transfusion; 2012 Jul; 52(7):1535-41. PubMed ID: 22229973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
    Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired von Willebrand syndrome in congenital heart disease surgery: results from an observational case-series.
    Icheva V; Nowak-Machen M; Budde U; Jaschonek K; Neunhoeffer F; Kumpf M; Hofbeck M; Schlensak C; Wiegand G
    J Thromb Haemost; 2018 Nov; 16(11):2150-2158. PubMed ID: 29908036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.